Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy

As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St. Louis to evaluate whether it benefited our patient population. Patients were risk-assessed using the Memorial Sloan Kettering Predictive Nom...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Schenone, Aaron D, Luo, Jingqin, Montgomery, Luke, Morgensztern, Daniel, Adkins, Douglas R, Van Tine, Brian A
Format: Artigo
Langue:Inglês
Publié: BlackWell Publishing Ltd 2014
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4101751/
https://ncbi.nlm.nih.gov/pubmed/24574357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.209
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires